BIOXCEL THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.07 USD | -0.96% |
|
-0.96% | -29.83% |
| May. 09 | BioXcel Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 09 | Transcript : BioXcel Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Presenter SpeechVincent O'Neill (Executives)Okay. I think we're ready to get started. So good ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioXcel Therapeutics, Inc. is a biopharmaceutical company utilizing artificial intelligence to develop medicines in neuroscience. Its subsidiary, OnkosXcel Therapeutics, develops medicines in immuno-oncology. The Companyâs most advanced neuroscience candidate, BXCL501, is an investigational, proprietary, orally dissolving film formulation of Dex in development for the treatment of agitation associated with psychiatric and neurological disorders. It is continuing to develop BXCL501 for the potential acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home setting and for the potential acute treatment of agitation (non-daily) associated with dementia due to probable Alzheimers disease in the at-home setting and in care facilities. Its most advanced immuno-oncology candidate, BXCL701, is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
2.07
USD
Average target price
7.25
USD
Spread / Average Target
+250.24%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -29.83% | 77.69M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -1.05% | 21.96B | |
| -14.15% | 21.87B | |
| -5.29% | 19.21B | |
| -4.16% | 18.08B | |
| -38.29% | 17.71B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- BTAI Stock
- News BioXcel Therapeutics, Inc.
- Transcript : BioXcel Therapeutics, Inc. - Special Call
